Compounded Tirzepatide vs Zepbound: Which Should You Choose in 2026?

Important Disclaimer: Compounded tirzepatide is NOT FDA-approved, has NOT undergone bioequivalence testing, and is NOT the same as, equivalent to, interchangeable with, or a generic version of the FDA-approved branded products Zepbound or Mounjaro. The FDA does not review or verify the safety, effectiveness, or quality of compounded medications before they are dispensed. The only FDA-approved tirzepatide products are the branded medications Zepbound and Mounjaro. This article is educational only and is not medical advice. Discuss all of your options, including FDA-approved products, with a licensed healthcare provider before starting, stopping, or changing any treatment.

⚠ Boxed Warning — Thyroid C-Cell Tumors. In studies in rodents, tirzepatide caused thyroid C-cell tumors. It is not known whether tirzepatide causes such tumors, including medullary thyroid carcinoma (MTC), in humans.

Tirzepatide is contraindicated in people with a personal or family history of MTC or in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Seek medical care promptly for a neck lump, hoarseness, trouble swallowing, or shortness of breath. Tell your clinician about your full medical and family history before starting or changing treatment.

Quick Answer: Compounded tirzepatide and the branded products Zepbound and Mounjaro all use tirzepatide as the active ingredient, but they are not the same product and should not be treated as interchangeable. Zepbound and Mounjaro are FDA-approved, have been through controlled clinical trials, and are manufactured under FDA oversight. Compounded tirzepatide is prepared by a compounding pharmacy for an individual patient based on a prescription; it is not FDA-approved, has not been bioequivalence-tested against the branded products, and is not reviewed by the FDA for safety, effectiveness, or quality before it is dispensed. This article explains those differences calmly and neutrally so you can have an informed conversation with your clinician.

What Zepbound, Mounjaro, and Compounded Tirzepatide Actually Are

It helps to start with plain definitions, because these three things occupy different regulatory categories even though they share an active ingredient.

Mounjaro is an FDA-approved branded tirzepatide product approved to improve blood sugar control in adults with type 2 diabetes. Zepbound is an FDA-approved branded tirzepatide product approved for chronic weight management in certain adults. Both are manufactured by the brand-name manufacturer and sold in standardized, pre-specified doses through the regular pharmaceutical supply chain.

Compounded tirzepatide is a preparation made by a compounding pharmacy for an individual patient based on a prescription. Compounding is the practice of preparing a medication tailored to a specific patient. A compounded preparation is a different product from the FDA-approved branded drug: it is not FDA-approved, it is not reviewed by the FDA before dispensing, and it has not been tested to show it behaves the same way in the body as Zepbound or Mounjaro.

For background on the active ingredient itself, see our tirzepatide injection guide.

”Same Active Ingredient” Is Not “the Same Medication”

A common point of confusion is the assumption that because compounded tirzepatide contains tirzepatide, it must be “the same as,” “just like,” or a “generic version of” Zepbound or Mounjaro. That is not accurate, and it is worth being precise about why.

A finished medication is more than its active ingredient. It is a specific formulation — the active ingredient plus inactive ingredients, at a specific concentration, prepared by a specific process, tested to specific standards, and packaged in a specific way. Two products can share an active ingredient and still differ in formulation, concentration, purity profile, stability, and how they are tested. A true generic drug, by contrast, is an FDA-approved product that has been demonstrated to be bioequivalent to a brand-name reference drug. Compounded tirzepatide is not a generic drug; no compounded tirzepatide has been approved by the FDA or shown to be bioequivalent to Zepbound or Mounjaro.

The honest framing is this: compounded tirzepatide and the branded products are related but distinct. Sharing an active ingredient does not make them equivalent or interchangeable.

FDA Approval: What It Means and Who Has It

FDA approval of a drug means the agency has reviewed substantial evidence — including controlled clinical trials, manufacturing details, and labeling — and concluded the product’s benefits outweigh its risks for its approved uses, and that it can be manufactured to consistent quality standards. Zepbound and Mounjaro have been through this process. Compounded tirzepatide has not.

This is not a statement that one is “better” and the other “worse.” It is a statement about a specific, verifiable difference in regulatory status. The FDA does not review compounded drugs for safety, effectiveness, or quality before they reach a patient. When a clinician and patient consider a compounded preparation, they are working outside the FDA-approval framework that applies to the branded products, and both should understand that clearly.

Bioequivalence Testing: Why It Matters Here

Bioequivalence testing is how regulators confirm that a non-brand product delivers the active ingredient into the bloodstream in essentially the same amount, and at essentially the same rate, as the reference product. It is the technical backbone of how an FDA-approved generic is shown to be interchangeable with a brand-name drug.

Compounded tirzepatide has not undergone bioequivalence testing against Zepbound or Mounjaro. That means there is no regulatory finding that a given compounded preparation delivers tirzepatide to the body in the same way the branded products do. This is one of the most important and most often overlooked differences. Without bioequivalence data, it is not correct to assume a compounded preparation will perform identically to the FDA-approved product — in either direction. The accurate statement is simply that it has not been tested to that standard.

Manufacturing, Testing, and Oversight

FDA-approved branded products are made under federal current Good Manufacturing Practice (cGMP) requirements and are subject to FDA oversight of the manufacturing process, with batch-level quality controls built into an approved manufacturing system.

Compounded preparations are regulated differently. Compounding pharmacies operate under a combination of federal law and state board of pharmacy oversight, and the specific standards depend on the practices of the specific pharmacy. The key point for this comparison is that the FDA does not approve, or pre-review for safety and quality, an individual compounded preparation the way it does an approved drug. Quality, purity, potency, and sterility for a compounded product depend heavily on the practices of the specific pharmacy preparing it. This is a structural difference in oversight, stated neutrally — not a claim that compounded products are inherently unsafe or that branded products are inherently superior in outcomes.

Side-by-Side Comparison

The table below summarizes the verifiable differences. It is intentionally neutral: it describes regulatory and process facts, not which option is “best.” That decision belongs to you and your clinician.

Factor	Zepbound / Mounjaro (FDA-approved)	Compounded Tirzepatide
FDA approval status	FDA-approved	Not FDA-approved
Reviewed by FDA before dispensing	Yes — safety, effectiveness, quality, and labeling reviewed	No — not reviewed for safety, effectiveness, or quality before dispensing
Bioequivalence tested vs. the branded product	Is the reference product	No — not bioequivalence-tested against Zepbound or Mounjaro
Is it a generic?	Branded; no FDA-approved generic at time of writing	No — not a generic and not interchangeable
Manufacturing standard	Federal cGMP under FDA oversight of an approved process	Prepared by a state-licensed 503A compounding pharmacy under state pharmacy board oversight; quality depends on the specific pharmacy’s practices
Clinical trial program	Studied in the SURMOUNT clinical trial program for the approved product	The specific compounded preparation has not been studied in those trials
Dosing	Standardized, pre-specified doses	Patient-specific, set by the prescribing clinician
Active ingredient	Tirzepatide	Tirzepatide (same active ingredient, different product)

What the Clinical Trial Data Does and Doesn’t Tell You

You will often see tirzepatide discussed alongside results from the SURMOUNT clinical trial program. It is important to attribute these figures correctly. In SURMOUNT-1, a trial of the FDA-approved branded tirzepatide product, participants on the highest studied dose lost, on average, about 20.9% of their body weight over the study period (Source: SURMOUNT-1, NEJM).

Several caveats apply, and they apply equally regardless of which product you are considering:

• These are group averages under controlled study conditions, not promises for any individual. Results vary widely from person to person and are not guaranteed.
• The figures come from studies of the FDA-approved branded product. They may not apply to compounded tirzepatide, which is a different, non-FDA-approved product that has not been studied in those trials and has not been bioequivalence-tested.
• Trial participants were enrolled under specific criteria and supported within a structured study, which differs from real-world use.

In short, SURMOUNT data describes the FDA-approved product. It should not be read as a prediction of what compounded tirzepatide will do for you. For more on how response can change over time, see our article on the tirzepatide weight-loss plateau.

The Current Regulatory Status of Compounded Tirzepatide

The regulatory landscape for compounded tirzepatide has shifted, and it is worth stating the current status plainly rather than relying on older rationales. As of 2025, tirzepatide is not on the FDA drug shortage list. Separately, the FDA has proposed regulatory changes that affect the compounding of tirzepatide (including a proposal published in April 2026). We mention this only to keep the picture accurate and current; it is not offered as a reason to choose one product over another. Regulatory information is current as of publication and is subject to change.

What this means for you practically: the decision about whether a compounded preparation is appropriate is a clinical and regulatory question best worked through with a licensed provider who can explain the current rules as they apply to your situation.

503A Compounding: What “State-Licensed” Means

503A compounding pharmacies prepare patient-specific medications for an individual patient, based on a valid prescription from a licensed prescriber. Each preparation is made to order for that specific patient; 503A pharmacies do not compound for general distribution. They operate primarily under state board of pharmacy oversight.

Here is the point that is most often misunderstood: a state-licensed 503A compounding pharmacy is not an FDA-approved drug manufacturer, and a compounded preparation is not an FDA-approved drug. The FDA does not review individual compounded preparations for safety, effectiveness, or quality before they are dispensed. Quality, purity, potency, and sterility for a compounded product depend on the practices of the specific pharmacy preparing it — a structural difference in oversight, stated neutrally and not as a claim that compounded products are inherently unsafe or that branded products are inherently superior in outcomes. For a deeper look at compounding categories and quality questions, see our complete guide to semaglutide, which covers the same regulatory framework for a related GLP-1 medication.

Questions to Ask Your Clinician

If you are weighing FDA-approved versus compounded options, an informed conversation matters more than any single fact. Consider asking:

• Given my medical history (including the thyroid C-cell boxed warning and contraindications), is tirzepatide appropriate for me at all?
• What are the differences between the FDA-approved product and a compounded preparation in my specific case?
• If a compounded preparation is being considered, what type of pharmacy prepares it, and what quality and sterility testing is done?
• What dose has been prescribed for me, and why? (Dosing should be set by your clinician, never self-adjusted.)
• What is the current regulatory status, and how might it affect my access or options?

Do not start, stop, switch products, or change your dose on your own. Any change in medication, formulation, product, or dose is a clinical decision to make with your provider. For guidance on discontinuation specifically, see stopping tirzepatide, and for lifestyle support during treatment, see the best diet on tirzepatide.

Frequently Asked Questions

Is compounded tirzepatide the same as Zepbound or Mounjaro?

No. They share the active ingredient tirzepatide, but compounded tirzepatide is a different product. It is not FDA-approved, has not been bioequivalence-tested against the branded products, and is not interchangeable with or a generic version of Zepbound or Mounjaro. The FDA does not review compounded preparations for safety, effectiveness, or quality before they are dispensed.

Is compounded tirzepatide a generic version of Zepbound?

No. A generic is an FDA-approved product shown to be bioequivalent to a brand-name reference drug. No compounded tirzepatide has been FDA-approved or shown to be bioequivalent to Zepbound or Mounjaro, so it is not a generic and should not be described as one.

Will compounded tirzepatide work the same as the branded product?

There is no bioequivalence data establishing that a compounded preparation performs the same way in the body as Zepbound or Mounjaro. Because it has not been tested to that standard, it is not accurate to assume it works the same — in either direction. Individual results vary and are not guaranteed. Discuss expectations with your clinician.

Do the SURMOUNT trial weight-loss numbers apply to compounded tirzepatide?

The SURMOUNT figures come from studies of the FDA-approved branded product. They are group averages under study conditions, results vary and are not guaranteed, and they may not apply to compounded tirzepatide, which is a different product that was not studied in those trials.

Why would someone consider compounded tirzepatide instead of the branded product?

That is a clinical decision to make with a licensed provider based on your individual situation. This article does not advocate one option over the other. The goal here is to make the real differences clear so you can have an informed conversation with your clinician about what is appropriate for you.

Can I adjust my own dose to match a Zepbound dosing schedule I read about?

No. Do not self-adjust your dose or copy a dosing schedule from elsewhere. Dosing is a clinical decision your prescriber makes for you individually. Changing your dose on your own can be unsafe.

Is the branded product safer than compounded, or is compounded safer than branded?

This article does not make a superiority claim in either direction. The verifiable difference is regulatory and procedural: the branded products are FDA-approved, reviewed, and made under FDA-overseen manufacturing, while compounded tirzepatide is not FDA-approved or pre-reviewed. How that applies to your safety depends on your individual circumstances and the specific pharmacy involved — discuss it with your clinician.

Talking With Contour Health

If you are trying to understand your options, an experienced clinician can walk you through the differences between FDA-approved and compounded products and help you decide what, if anything, is appropriate for you. Compounded tirzepatide is not FDA-approved, and the FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed. Learn more about our compounded tirzepatide program, or explore our full weight-loss collection to compare options with your care team.

Related Articles

• Complete Guide to Semaglutide
• Tirzepatide Injection Guide
• Tirzepatide Weight-Loss Plateau
• Stopping Tirzepatide
• Best Diet on Tirzepatide

---

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved and should only be used under the supervision of a licensed healthcare provider. Individual safety and effectiveness may vary, and no outcome is guaranteed. Always discuss FDA-approved options and your full medical history with your clinician before starting, stopping, or changing any treatment.

Regulatory Disclaimer: Compounded tirzepatide is not FDA-approved. The FDA does not review or verify the safety, quality, or effectiveness of compounded drugs before they are dispensed. Compounded tirzepatide has not undergone bioequivalence testing and has not been demonstrated to be equivalent to, interchangeable with, or a generic version of Zepbound or Mounjaro. Information about FDA regulations is current as of the publication date and is subject to change.